Ironwood Pharmaceuticals traded at $11.91 this Tuesday December 6th, decreasing $0.10 or 0.79 percent since the previous trading session. Looking back, over the last four weeks, Ironwood Pharmaceuticals lost 1.23 percent. Over the last 12 months, its price rose by 4.06 percent. Looking ahead, we forecast Ironwood Pharmaceuticals to be priced at 11.86 by the end of this quarter and at 10.75 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
11.91
Daily Change
-0.79%
Yearly
4.06%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,980.00 25.00 0.63% 26.35%
Astellas Pharma 2,092.00 3.00 0.14% 17.46%
Acadia Pharmaceuticals 14.91 -0.33 -2.17% -30.07%
Agios Pharmaceuticals 28.45 -1.35 -4.53% -12.97%
Akebia Therapeutics 0.28 -0.01 -3.22% -89.56%
Almirall SA 9.38 -0.08 -0.79% -12.09%
Alnylam Pharmaceuticals 216.88 -9.32 -4.12% 20.30%
Amarin 1.19 0.01 0.42% -67.89%
Ardelyx 1.81 -0.05 -2.69% 24.83%
AstraZeneca 11,150.00 -110.00 -0.98% 35.60%
AstraZeneca 68.61 0.19 0.27% 25.28%
Bluebird Bio 7.85 -0.16 -2.00% -21.11%
Coherus Biosciences 6.72 -0.02 -0.30% -62.58%
Charles River Laboratories 208.57 -6.54 -3.04% -43.13%
Emergent BioSolutions 11.96 0.17 1.40% -71.67%
Esperion Therapeutics 7.33 -0.17 -2.20% 31.74%
Exact Sciences 46.06 0.51 1.12% -44.75%
Halozyme Therapeutics 56.30 0.36 0.64% 74.03%
Intercept Pharmaceuticals 13.96 -0.36 -2.48% -17.61%
Incyte Corp 82.57 -1.51 -1.80% 23.74%
Ironwood Pharmaceuticals 11.91 -0.10 -0.79% 4.06%
Karyopharm Therapeutics 5.10 -0.14 -2.58% -29.82%
Lexicon Pharmaceuticals 2.11 -0.05 -2.31% -51.27%
MacroGenics 6.04 -0.35 -5.41% -64.93%
Moderna Inc 173.75 -2.18 -1.24% -38.46%
Myriad Genetics 19.54 -0.47 -2.35% -24.99%
Puma Biotechnology 4.32 0.01 0.23% 40.26%
Pacira 47.06 0.31 0.66% -17.15%
PTC Therapeutics 39.49 -1.63 -3.96% 4.11%
Ultragenyx Pharmaceutical 39.12 -0.72 -1.80% -53.68%
Sarepta Therapeutics 119.87 -3.09 -2.51% 40.48%
Vanda Pharmaceuticals 10.65 0.04 0.38% -34.46%

Indexes Price Day Year
USND 10967 -272.69 -2.43% -30.09%
US2000 1804 -36.00 -1.96% -19.95%

Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company. The Company is focused on the development and commercialization of GI product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC). It operates in human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C in Japan and China. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries.